Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors

J. S L Kloth, A. Pagani, M. C. Verboom, A. Malovini, C. Napolitano, W. H J Kruit, S. Sleijfer, N. Steeghs, A. Zambelli, R. H J Mathijssen

Research output: Contribution to journalArticlepeer-review


Background: Tyrosine kinase inhibitors (TKIs) are associated with prolongation of the QTc interval on the electrocardiogram (ECG). The QTc-interval prolongation increases the risk of life-threatening arrhythmias. However, studies evaluating the effects of TKIs on QTc intervals are limited and only consist of small patient numbers. Methods: In this multicentre trial in four centres in the Netherlands and Italy we screened all patients who were treated with any TKI. To evaluate the effects of TKIs on the QTc interval, we investigated ECGs before and during treatment with erlotinib, gefitinib, imatinib, lapatinib, pazopanib, sorafenib, sunitinib, or vemurafenib. Results: A total of 363 patients were eligible for the analyses. At baseline measurement, QTc intervals were significantly longer in females than in males (QTcfemales =404 ms vs QTcmales =399 ms, P=0.027). A statistically significant increase was observed for the individual TKIs sunitinib, vemurafenib, sorafenib, imatinib, and erlotinib, after the start of treatment (median ΔQTc ranging from +7 to +24 ms, P

Original languageEnglish
Pages (from-to)1011-1016
Number of pages6
JournalBritish Journal of Cancer
Publication statusPublished - Mar 17 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this